Citius Oncology prices $9 million offering; shares down over 5%
Source: SeekingAlpha
2025-09-09 08:42:16 ET
More on Citius Pharmaceuticals, Citius Oncology
- Citius Oncology: Is A Lymphir Launch Coming Too Late?
- Citius Oncology announces pricing of $9 million public offering
- Cencora distribution deal boosts Citius shares
- Seeking Alpha’s Quant Rating on Citius Pharmaceuticals
- Historical earnings data for Citius Pharmaceuticals
Read the full article on Seeking Alpha
For further details see:
Citius Oncology prices $9 million offering; shares down over 5%
Citius Oncology Inc.
NASDAQ: CTOR
CTOR Trading
-8.86% G/L:
$0.82 Last:
275,721 Volume:
$0.93 Open:
CTOR Latest News
March 10, 2026 08:47:00 am
Citius Oncology Announces Positive Topline Results from Investigator?Initiated Phase 1 Study of LYMPHIR(TM) in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers
March 04, 2026 09:15:00 am
Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR(TM) (E7777) Dosing Prior to Commercial CAR?T Therapy in High?Risk Diffuse Large B?Cell Lymphoma
February 17, 2026 08:24:00 am
The FDA Cleared 50 Oncology Approvals in 2025 and the Pipeline Keeps Accelerating
February 13, 2026 08:00:00 am
Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR(TM)
